Pacira BioSciences - PCRX Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCRX shares.
View PCRX analyst ratings or view top-rated stocks.

7 analysts have issued 12-month target prices for Pacira BioSciences' shares. Their PCRX share price forecasts range from $50.00 to $80.00. On average, they expect the company's stock price to reach $64.36 in the next year. This suggests a possible upside of 57.7% from the stock's current price.
View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts.

Pacira BioSciences' stock was trading at $38.61 on January 1st, 2023. Since then, PCRX stock has increased by 5.7% and is now trading at $40.81.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our PCRX earnings forecast.

Pacira BioSciences, Inc. (NASDAQ:PCRX) issued its quarterly earnings data on Tuesday, February, 28th. The company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.71 by $0.11. The firm had revenue of $171.96 million for the quarter, compared to analyst estimates of $174.12 million. Pacira BioSciences had a trailing twelve-month return on equity of 11.09% and a net margin of 2.39%.

ETFs with the largest weight of Pacira BioSciences (NASDAQ:PCRX) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), iShares U.S. Pharmaceuticals ETF (IHE), First Trust Horizon Managed Volatility Small/Mid ETF (HSMV) and First Trust Multi-Manager Small Cap Opportunities ETF (MMSC).

Pacira BioSciences issued an update on its FY22 earnings guidance on Thursday, January, 5th. The company provided earnings per share (EPS) guidance of at least $2.50 for the period, compared to the consensus EPS estimate of $2.64. The company issued revenue guidance of $666.8 million, compared to the consensus revenue estimate of $676.64 million.

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PCRX stock can currently be purchased for approximately $40.81.

Pacira BioSciences (NASDAQ:PCRX) has a market capitalization of $1.88 billion and generates $666.82 million in revenue each year. The company earns $15.91 million in net income (profit) each year or $0.31 on an earnings per share basis.

The company employs 697 workers across the globe.

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The official website for the company is www.pacira.com. The company can be reached via phone at (813) 553-6680, via email at susan.mesco@pacira.com, or via fax at 302-655-5049.